7 ms·
FTC warns pharma companies about sham patent listings designed to delay generics
- ConceptJunkie 3y ago[flagged]
- HankB99 3y agoKey phrase from the first paragraph: > ... FTC is now warning pharma that it might finally start cracking down. Sounds like a fishing expedition.
- Daishiman 3y agoRegulatory agencies have a knack for warning market players to clean up their act before stepping in.
- munk-a 3y agoIt legitimately tends to be the cheaper way to regulate. You've basically got two options: 1) give a big warning and hope you get a majority change in the industry because they can see the writing on the wall or 2) change the rules and, as immediately as is appropriate, open a bunch of lawsuits... then spend the next decade in the courts spending immense amounts of money while every one of the offending parties runs a big PR campaign about being singled out to comply with a rule that most of the other companies aren't complying with. Politics is ugly and rarely will the straightforward approach be the easiest and cheapest.
- HankB99 3y agoYes, that makes more sense than a fishing expedition.
- deleted 3y ago[deleted]
- droopyEyelids 3y agoI followed Lina Kahn (FTC chair) on Twitter before Biden appointed her, and I was kind of blown away that it happened. She had a very clear philosophical opposition to a lot of the way things are done in this country. And I mean, I followed her because I agreed! But my preferences are not mainstream. Amazing to see her slinging rocks at giants from this position.
- throwaway128128 3y agoBiden's had a number of appointments that have been surprisingly on point. I really like how antitrust enforcement is finally, FINALLY getting some teeth.
- throe37848 3y agoMaybe it was her surname. This "hipster antitrust" approach is a nice smoke screen big pharma needs. India and other countries already make generics, there is no need to wait several years for US manufacturers. FTC is just a road block that prevents cheap medical imports.
- emodendroket 3y agoIs it really though. Even with the current level of regulation we have more than enough scandals with, say, artificial tears that blinded people who used them.
- partitioned 3y agoFDA should be able to make sure imports are safe
- alwayslikethis 3y agoIt's all a trade off. We can have more affordable medicine by importing it. This means more people will be able to access it, meaning less bankruptcies, which isn't any good for one's health. Will it be less safe than the ones you can currently get for an exorbitant prices? Marginally, probably. Overall, society can benefit from letting people import their medicine. It will also drive down prices and force big pharma to drop their prices.
- NeuroCoder 3y agoAs much as I'd love to see ridiculous parent laws in medicine get under control, I have very little confidence that Lina Kahn would accomplish anything. She doesn't have a great track record. You really need someone with a good background in patent law specifically for pharmaceuticals to take this on
- deleted 3y ago[deleted]
- deleted 3y ago[deleted]
- deleted 3y ago[deleted]
- rsashwin 3y agoDefinitely, experience matters. However, I am used to an FTC that turns a blind eye on these Pharma antics. So, as long as FTC takes these kind of cases on, I am all for it. Even the price of generics are way out of line when compared to the generics you get outside of US. Similarly, a lot of Mergers have resulted in fewer competition in the market, leading to rampant price inflation. Federal institutes like FTC need to step up their game here.
- NeuroCoder 3y agoI guess increasing awareness on the issue is better than nothing. I've just noticed that she has a gift for identifying problematic industries but struggles to come up with clear criticisms that could translate into pragmatic solutions.
- thenerdhead 3y agoMaybe they can add a third clause to be “safe, effective, and accessible”? The history of the FDA is pretty interesting and disappointing to say the least. Especially with the supplement craze.
- imiric 3y agoI don't know how the US public can take any of the federal regulatory agencies seriously, given their history of corruption[1]. We only hear about cases that happen to leak, but who knows how many go undiscovered. It's easy to be conspiratorial about this and assume that the corruption happens at the highest levels of government. [1]: https://www.businessinsider.com/fda-chief-approved-oxycontin-six-figure-gig-at-purdue-pharma-2021-5 https://www.businessinsider.com/fda-chief-approved-oxycontin...
- thenerdhead 3y agoPaul Offit writes about the FDA history in his book "Do you believe in Magic?". His argument is that the FDA tends to try to do what is "right" but the public opinion gets swayed to the point where it becomes political and we "do this to ourselves".
- AlbertCory 3y agoI have to admit I didn't know how the Orange Book worked, so I had to do some research. Do I have this right? "An Orange Book listing shows "approved prescription drugs, related patent and exclusivity information, and therapeutic equivalence evaluations, along with other information." https://www.fda.gov/drugs/news-events-human-drugs/our-perspective-orange-book-40-valued-fda-resource-continually-enhanced-user-input https://www.fda.gov/drugs/news-events-human-drugs/our-perspe... So a pharma company can insert a listing saying that, for a bogus example, "Vioxx has no approved generics, because all substitutes are under patent or patent pending." when that is untrue. This seems clearly illegal and abusive. From the headline, I thought Kahn was saying that filing a trivial patent "improving" Vioxx would be illegal. But that's not it.
- pixl97 3y agoI believe the word you are looking for is fraudulent. And yea, why aren't we prosecuting for that.
- whymauri 3y agoNot only bogus, but if you get a hit on a scaffold you can combinatorially modify that scaffold and file it with the patent. This effectively blocks the small permutation space around the drug from further investigation or development. There's lot of promising science that can't be done because incumbents are so adversarial about patent space for structures they don't even care about. To make matters worse, patent data and notation is: * Poorly structured and defined, * Difficult to parse, * Uses combinatorial/wildcard notation (Markush structures [0], which is what modern drug patent law is based on). So it's a total mess. The best analogy I could give for software is: imagine if you could patent closed source code (the literal code) and also attach a wildcard to every branch in logic within that closed source code, but all you publish are the filenames (as screenshots of directories, not text). You don't have to run due diligence that the permutations are run to spec or even compile, but now nobody can write logic infringing on your hypothetical code (which you never wrote). If your reaction is 'what the fuck?', yes I agree. [0] https://en.wikipedia.org/wiki/Markush_structure https://en.wikipedia.org/wiki/Markush_structure
- 3y ago
- adolph 3y agoAt first I thought this was about minor changes to formulations that can be granted new patents, a problem which seems to me to be to be outside the FTC's purview. It looks like the problem is more like out and out fraud: Brand drug manufacturers are responsible for ensuring their patents are properly listed. Yet certain manufacturers have submitted patents for listing in the Orange Book that claim neither the reference listed drug nor a method of using it. . . . courts have recognized that improperly listing patents in the Orange Book may constitute an “improper means” of competition. Accordingly, improperly listing patents in the Orange Book may also be worthy of enforcement scrutiny from government and private enforcers under a monopolization theory.
- AlbertCory 3y agoMy take: she has a solid case on this. You build credibility by winning. She hasn't done a good job on that.
- junofan 3y agoThe FTC’s statement cites a Shkreli case. I wouldn’t get my hopes up.
- DangitBobby 3y agoIt is quite clearly fraud. For some reason we don't seem to prosecute companies for fraud.
- jacquesm 3y agoWhy warn them? Just do it already.
- deleted 3y ago[deleted]
- munk-a 3y agoI like the sentiment - but this is probably the "just do it already". Real warnings happen behind closed doors - this is probably a "We're going to create a PR nightmare if you don't fix your act, this is the first step on the public being very very mad. And we'd rather like to avoid going to court against your super-lawyers."
- jacquesm 3y agoJust revoke a corporate charter or two of the most frequent abusers. That will certainly get the attention of those that remain. Then you can warn them that they're next if they don't change tack pronto. Big companies are next to invulnerable when you treat them using the same playbook as you would a jaywalker or a person the runs a red light. They love their court cases because they have lawyers on retention and it helps them build an even stronger moat: the moat made up out of negligible legal costs at scale that would criple smaller players. So only large players remain. But revoking a corporation's charter instantly crushes that angle of defense and it is used far too sparingly. After that the shareholders get to pick over the leftovers. It's the corporate equivalent of the death penalty and since these companies are responsible for the lives of those that depend on affordable medication this sort of money grab is a reason people have reduced quality of life or die. It's beyond disgusting and such abuses deserve the harshest penalties available, not a slap on the wrist or a 'stop being soooo naughty' message. Corporations exist by the grace of governments recognizing them as such. They want to be 'people' when it suits them and eternal constructs with zero responsibility when that suits them instead. I think we should treat them a bit more like people and kill a couple of the worst abusers. See if that angle yields the right response.
- pests 3y ago
- SuperNinKenDo 3y agoThese people won't stop lobbying to have this kind of exclusivity respected in other jurisdictions as well. Whether through the US government or directly, they've constantly pressured us here in Australia to "respect" the same privileges they enjoy in the US. Thank God we have largely resisted these efforts so far. Generics here are highly available for almost anything at the consumer level. Those who can afford to often buy name brand anyway, because of psychological reasons I guess, so pharmaeceutical companies still make stacks of cash, without poor people jeeding to spend half their weekly income on basic meds. I understand and appreciate that the US government doesn't arbitrarily begin semi-retributive campaigns, and instead attempts to have companies self-correct. But in instances like this of obvious, wilful abuse of the law, there should be some drawing of blood frankly. It strikes me as a little pathetic that these agencies are always issuing "warnings" that they might actually start enforcing regulations. It's exactly this that makes these companies feel they have license to behave this way, because they know they'll have plenty of time to clean up if the laws actually start getting enforced, and they'll have made a tidy profit at everybody else's expense in the meantime.
- virgulino 3y agoI've been taking the "blockbuster drug", Humira/Adalimumab, for more than 10 years. Humira alone is estimated to have generated US$200 billion in profits for a single company. Its history, its legal and commercial maneuvers are appalling and possibly the poster child for what is wrong with the patent system. And how public money originally funds much of the research into these drugs. This year I finally started taking a biosimilar. Still extremely expensive. I don't have to pay for it, I sued the government to get it, here in Brazil. Unfortunately, this is not an uncommon situation. Our constitution guarantees our right to health and the government's obligation to provide it. https://www.npr.org/sections/health-shots/2023/07/20/1188745297/humira-threatened-by-yusimry-low-cost-rival https://www.npr.org/sections/health-shots/2023/07/20/1188745... https://en.wikipedia.org/wiki/Adalimumab#Patent_litigation https://en.wikipedia.org/wiki/Adalimumab#Patent_litigation
- AlbertCory 3y ago[flagged]
- effingwewt 3y agoHe specifically said it was in Brazil. Saying 'not to be pedantic' doesn't make it any less so.
- glint 3y agoFor those interested, the relevant section looks like Title 8 Section II Article 196. Here's an html copy of the official MPF English translation: https://pdba.georgetown.edu/Constitutions/Brazil/brtitle8.html https://pdba.georgetown.edu/Constitutions/Brazil/brtitle8.ht...
- AlbertCory 3y ago[flagged]
- pavon 3y agoA right to health absolutely exists in Brazil: > TITLE 8 SECTION II Article 196. Health is a right of all and a duty of the State and shall be guaranteed by means of social and economic policies aimed at reducing the risk of illness and other hazards and at the universal and equal access to actions and services for its promotion, protection and recovery.[1] [1]https://www.stf.jus.br/arquivo/cms/legislacaoConstituicao/anexo/brazil_federal_constitution.pdf https://www.stf.jus.br/arquivo/cms/legislacaoConstituicao/an...
- ilaksh 3y agoIf they were serious then they would put the CEOs in jail.
- tourmalinetaco 3y agoThe point of a CEO is as a fall guy. Only going after the CEO means nothing is solved, the hydra remains. Instead you have to decapitate the company’s leading structure, such as investors and high management, then hope for a systemic change which may or may not come.
- lost_tourist 3y agoI agree, seize the company and take ownership of all its assets, including IP, at a minimum. Fines and punishments with no teeth are not any good for the public interest.
- olliej 3y agoBut what about the harm that does to the shareholders? I wish I were being facetious, but while a lot of scummy people and companies own shares, a lot more just move cash in various forms out of the company into independent entities. If the company has all its assets seized by some mechanism, presumably all the large shareholders: pension funds, 401ks, etc are subject to even more penalties and there are no assets or even potential future income to compensate them. Essentially you get the Great Recession or Enron effect where large numbers of retired or near retirement people suddenly no longer had pensions or retirement savings. Your only real option is to charge all the individuals involved and send them to jail, and fines for everyone and everything else - though the fines for the company have to be more than the potential profit by a large amount. Otherwise you run into a problem where say one person working for the company wants a bonus and realizes a fraudulent listing would get him that bonus? In your model that one person functionally bankrupts the company vs fining and jailing that person and fining the corporation for failing to ensure adequate controls on entries to the orange book.
- 3y ago
- m3kw9 3y agoWhy not insert every drug so it don’t go generic? I’m not getting how this orange book works
- m3kw9 3y agoAlso if it’s patented it cannot be made generic, if expired it can. What’s the point of using the orange book?
- flakeoil 3y agoYeah, I wonder too. A patent should be registered with the patent office and everyone can search there to see if there is something and what it covers and when it expires. What's this orange book all about. Some easier to search database? Why can big pharma enter stuff themselves and why does the FTC not check this? Seems absurd. Can it be that the orange book is an invention by big pharma and their lobby?
- m3kw9 3y agoI think they modify it a bit, parent that, put it in orange book, have insurance companies recommend this instead of the original, it could deter the generic makers because patients will be looking for the modified version say(extra long release).
- hedora 3y agoDoes this mean we can finally have the already-approved, over-17-year-old, and not-produced Lyme disease vaccine?
- Vecr 3y agoTo do that for any drug, the FDA needs to approve the new factory setup at a minimum, and that would probably take at least 3 years in practice. Problem is, vaccines are biologicals and you don't get generics for biologicals so that's out from the start. You'd have to re-do at least part of the trials to get a biosimilar licensed.
- eximius 3y agoOur regulators need to find some conviction. Just do it already.
- sizzle 3y agoBiosimilars couldn’t come sooner.
- zugi 3y agoSo one government agency - the USPTO - grants temporary monopolies to inventors as patents. Then another government agency - the FDA - restricts the drugs people can take to those specifically prescribed by a doctor, and then restricts pharmacies to making a very limited set of substitutions as "generics". Now since that system is messed up, we're involving yet a third agency, the FTC, to complain about companies using the letter of the law to avoid advertising the existence of competitor's products. Instead why dont we jist fix the broken USPTO and FDA systems? Shorten drug patents from 20 years to 10 or so? Stop allowing patents for trivial changes. Allow pharmacies to suggest generic substitutions. Etc. Pulling in a third government agency into the mix to fix the failures of the first two seems like the wrong approach.